Comparison of rituximab originator (MabThera ® ) to biosimilar (Truxima ® ) in patients with multiple sclerosis
Rituximab's originator MabThera or Rituxan has demonstrated high efficacy in multiple sclerosis (MS). Because of the patent expiration, rituximab biosimilars have been developed. However, because a biosimilar is not the exact copy of the originator, the efficacy and safety of a biosimilar may s...
Saved in:
Published in | Multiple sclerosis Vol. 27; no. 4; p. 585 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.04.2021
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | Rituximab's originator MabThera
or Rituxan
has demonstrated high efficacy in multiple sclerosis (MS). Because of the patent expiration, rituximab biosimilars have been developed. However, because a biosimilar is not the exact copy of the originator, the efficacy and safety of a biosimilar may significantly differ.
To compare the efficacy and safety of the biosimilar Truxima
and the originator MabThera
in MS.
Consecutive MS patients receiving MabThera
or Truxima
were prospectively followed during 1 year after treatment introduction. Allocation to each treatment depended on the period of introduction and not the physician's choice. Lymphocyte count, clinical and magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS), and adverse events were compared.
In total, 105 and 40 patients received MabThera
and Truxima
, respectively. The two groups did not differ in baseline characteristics. Effect on CD19+ lymphocytes and disease activity were similar during follow-up. EDSS remained stable, with no difference between groups. Adverse events were similar between groups.
The efficacy and safety of the rituximab biosimilar Truxima
seem equivalent to the originator MabThera
in MS patients. Truxima
could represent a relatively cheap and safe therapeutic alternative to MabThera
and could improve access to highly efficient therapy for MS in low- or middle-income countries. |
---|---|
ISSN: | 1477-0970 |
DOI: | 10.1177/1352458520912170 |